Skip to main content
PACIFIC EDGE LIMITED logo

PACIFIC EDGE LIMITED — Investor Relations & Filings

Ticker · PEB ISIN · NZPEBE0002S1 LEI · 9845007EDCF068FFEA12 ASX Professional, scientific and technical activities
Open in API
Filings indexed 747 across all filing types
Latest filing 2023-10-16 Share Issue/Capital Cha…
Country NZ New Zealand
Listing ASX PEB

About PACIFIC EDGE LIMITED

https://www.pacificedgedx.com/

Pacific Edge Limited is a cancer diagnostics company specializing in the development and commercialization of non-invasive molecular diagnostic tests. The company's primary product suite, Cxbladder, utilizes advanced mRNA biomarker technology to detect and monitor bladder cancer from urine samples. These genomic tests are designed to assist clinicians in the evaluation of patients presenting with hematuria and in the ongoing surveillance of patients previously diagnosed with the disease. By providing high sensitivity and negative predictive value, the Cxbladder suite helps to accurately rule out urothelial carcinoma, potentially reducing the requirement for invasive clinical procedures such as cystoscopy. The company focuses on integrating its diagnostic tools into standard clinical pathways to improve patient outcomes and healthcare efficiency.

Recent filings

Filing Released Lang Actions
ASX Appendix 3H – Options Lapsed
Share Issue/Capital Change Classification · 95% confidence The document is titled 'Notification of cessation of +securities' and details the lapse of options (securities) for Pacific Edge Limited. It provides specific information about the securities that have ceased, including the number, reason for cessation, and dates. The document is an announcement about changes in the company's issued capital related to securities that have lapsed or ceased. It does not contain financial statements, management discussion, or detailed financial data. It is not a full report but an announcement of a capital change event. Therefore, it fits best under the category of Share Issue/Capital Change (SHA). The document length is 3752 characters, which is relatively short and consistent with an announcement rather than a full report.
2023-10-16 English
Notification of cessation of securities - PEB 4 pages 23.8KB
Regulatory Filings Classification · 95% confidence The document is titled 'Notification of cessation of +securities' and details the lapse of options (securities) for Pacific Edge Limited. It provides specific information about the securities that have ceased, the reason for cessation, and the updated issued capital following these changes. The document is an announcement about changes in the company's securities, specifically the cessation of certain options, rather than a financial report or detailed analysis. It does not contain financial statements or management discussion but is a regulatory announcement about securities status changes. This fits best with the category of Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other specific categories.
2023-10-15 English
Quarterly Update – Q2 24 Cxbladder Test Volumes Resilient
Capital/Financing Update Classification · 85% confidence The document is a company announcement dated 11 October 2023, providing an update on test volumes processed in the second quarter of the 2024 financial year. It discusses operational impacts, quarterly and year-over-year volume changes, and provides contact information for investors and media. The content is focused on operational metrics and business updates rather than detailed financial statements or comprehensive financial performance. The document length is 3320 characters, which is relatively short and does not contain detailed financial data or analysis. It is not a full financial report like an Annual Report (10-K) or Interim Report (IR), nor is it a regulatory filing or certification. It is an operational update likely intended for investors and the market. Therefore, the most appropriate classification is Capital/Financing Update (CAP), as it relates to business activity and operational performance updates relevant to investors.
2023-10-10 English
Quarterly Update - Q2 24 Cxbladder Test Volumes Resilient 12 pages 1.9MB
Interim / Quarterly Report Classification · 95% confidence The document is an investor update from Pacific Edge dated October 2023, discussing quarterly test volumes for Q2 of the 2024 financial year, operational restructuring, Medicare coverage updates, and strategic initiatives. It contains detailed operational and financial performance data for a quarter shorter than a full fiscal year, including test volumes, clinician ordering statistics, and business strategy commentary. The document is comprehensive and substantive, not merely an announcement or a brief summary. It is not a full annual report but rather a detailed quarterly update with financial and operational data. Therefore, it fits the definition of an Interim / Quarterly Report (IR). Q2 2024
2023-10-10 English
FDA Signals Intent to Regulate Lab Developed Tests
Regulatory Filings Classification · 95% confidence The document is a company announcement discussing the FDA's proposed regulatory changes regarding Laboratory Developed Tests (LDTs). It includes commentary on the implications of the FDA's proposed rule, references to public comment periods, and links to external regulatory documents. There are no financial statements, earnings data, or detailed management analysis. The document is primarily an update on regulatory developments affecting the company and its industry, not a financial report or formal filing. It does not fit into categories like Annual Report, Interim Report, Earnings Release, or Audit Report. It is also not a direct regulatory filing or certification but rather a company announcement about regulatory changes and their potential impact. Given the nature and content, the best fitting category is Regulatory Filings (RNS), which serves as a fallback for miscellaneous regulatory announcements that do not fit other categories.
2023-10-01 English
FDA Signals Intent to Regulate Lab Developed Tests 2 pages 126.9KB
Regulatory Filings Classification · 95% confidence The document is a company announcement discussing the FDA's proposed regulatory changes regarding Laboratory Developed Tests (LDTs) and the potential impact on the company's business. It includes commentary from the CEO, references to regulatory proposals, and links to external sources. There are no financial statements, earnings data, or detailed financial analysis present. The document is informational about regulatory developments and company positioning rather than a financial report or formal filing. It does not fit into categories like Annual Report, Interim Report, Earnings Release, or Audit Report. It is not a voting result, management change, or capital update. The content is best classified as a Regulatory Filing (RNS) because it is a general regulatory announcement and company commentary on regulatory matters without detailed financial data or formal report structure.
2023-10-01 English

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.